TapewireFind a company

person · Reporting owner

Grunberg Gregory

Disclosed activity across 2 companies

Tapewire entity
116989
SEC CIK
0001711080

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
89bio, Inc.ETNB · Entity 73682Director · 10% ownerFebruary 09, 2023February 13, 2023
KALA BIO, Inc.KALA · Entity 7964DirectorJune 17, 2021June 21, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

89bio, Inc.

Report date February 09, 2023 · Filed February 13, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.70 · Expires 2033-02-09Direct27,400 Reported balance After 2023-02-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-02-09 · Grant · Acquired 27,400 · Balance 27,400

F1: This option represents a right to purchase a total of 27,400 shares of the Issuer's Common Stock, which will vest in full on February 9, 2024, subject to the Reporting Person's continued service to the Issuer through such date.

Filing footnotes · ownership attribution and instrument terms

F1: This option represents a right to purchase a total of 27,400 shares of the Issuer's Common Stock, which will vest in full on February 9, 2024, subject to the Reporting Person's continued service to the Issuer through such date.

KALA BIO, Inc.

Report date June 17, 2021 · Filed June 21, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect40,000 Reported balance After 2021-06-17 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2021-06-17 · Grant · Acquired 20,000 · Balance 40,000

F1: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service with the Issuer, the RSUs will vest as to 100% of the shares underlying the RSUs on the earlier of (i) June 17, 2022 or (ii) the date of the first annual meeting following June 17, 2021.

F2: Includes 20,000 unvested RSUs.

Common StockSEC Table I · non-derivativeIndirectBy Longitude Venture Partners IV, L.P.2,534,854 Reported balance Holding disclosure · report date 2021-06-17 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 2,534,854

F3: Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of Longitude Venture Partners IV, L.P. ("LVP IV") and may be deemed to have voting and investment power with respect to such securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP IV and may be deemed to share voting and investment power over the securities held by LVP IV. The Reporting Person is a member of LCP IV and may be deemed to share voting and investment power over the securities of the issuer held by LVP IV. Mr. Enright, Ms. Tammenoms Bakker and the Reporting Person (a member of the Issuer's board of directors) disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectBy Longitude Venture Partners II, L.P.2,877,006 Reported balance Holding disclosure · report date 2021-06-17 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 2,877,006

F4: Longitude Capital Partners II, LLC ("LCP II") is the general partner of Longitude Venture Partners II, L.P. ("LVP II") and may be deemed to have voting and investment power with respect to such securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP II and may be deemed to share voting and investment power over the securities held by LVP II. The Reporting Person is a member of LCP II and may be deemed to share voting and investment power over the securities of the issuer held by LVP II. Mr. Enright, Ms. Tammenoms Bakker and the Reporting Person (a member of the Issuer's board of directors) disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service with the Issuer, the RSUs will vest as to 100% of the shares underlying the RSUs on the earlier of (i) June 17, 2022 or (ii) the date of the first annual meeting following June 17, 2021.

F2: Includes 20,000 unvested RSUs.

F3: Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of Longitude Venture Partners IV, L.P. ("LVP IV") and may be deemed to have voting and investment power with respect to such securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP IV and may be deemed to share voting and investment power over the securities held by LVP IV. The Reporting Person is a member of LCP IV and may be deemed to share voting and investment power over the securities of the issuer held by LVP IV. Mr. Enright, Ms. Tammenoms Bakker and the Reporting Person (a member of the Issuer's board of directors) disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

F4: Longitude Capital Partners II, LLC ("LCP II") is the general partner of Longitude Venture Partners II, L.P. ("LVP II") and may be deemed to have voting and investment power with respect to such securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP II and may be deemed to share voting and investment power over the securities held by LVP II. The Reporting Person is a member of LCP II and may be deemed to share voting and investment power over the securities of the issuer held by LVP II. Mr. Enright, Ms. Tammenoms Bakker and the Reporting Person (a member of the Issuer's board of directors) disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 09, 2023 Filed Feb 13, 2023 17:34 UTC 89bio, Inc. ETNB · Entity 73682 GrantStock Option (Right to Buy) · Derivative 27,400 $0.00 Strike: $14.70 $0.00
Disclosure

SEC source: 0000899243-23-004799 · doc4.xml · derivative · entry 1

Grunberg Gregory · CIK 0001711080 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,400

Underlying: Common Stock · 27,400 shares

Expires 2033-02-09

F1 · derivative.exercise_date: This option represents a right to purchase a total of 27,400 shares of the Issuer's Common Stock, which will vest in full on February 9, 2024, subject to the Reporting Person's continued service to the Issuer through such date.

Read SEC document
May 16, 2022 Filed May 18, 2022 16:05 UTC 89bio, Inc. ETNB · Entity 73682 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $2.64 $0.00
Disclosure

SEC source: 0000899243-22-018587 · doc4.xml · derivative · entry 1

Grunberg Gregory · CIK 0001711080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-05-16

F1 · derivative.exercise_date: This option represents a right to purchase a total of 25,000 shares of the Issuer's Common Stock, which will vest in full on May 16, 2023, subject to the Reporting Person's continued service to the Issuer through such date.

Read SEC document
June 17, 2021 Filed Jun 21, 2021 17:30 UTC KALA BIO, Inc. KALA · Entity 7964 GrantCommon Stock 20,000 $0.00 $0.00
Disclosure

SEC source: 0001415889-21-003120 · form4-06212021_050601.xml · nonDerivative · entry 1

Grunberg Gregory · CIK 0001711080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service with the Issuer, the RSUs will vest as to 100% of the shares underlying the RSUs on the earlier of (i) June 17, 2022 or (ii) the date of the first annual meeting following June 17, 2021.

F2 · balance_after: Includes 20,000 unvested RSUs.

Read SEC document
April 21, 2021 Filed Apr 23, 2021 17:27 UTC 89bio, Inc. ETNB · Entity 73682 SaleCommon Stock 850 $27.60 $23,460.00
Disclosure

SEC source: 0000899243-21-016878 · doc4.xml · nonDerivative · entry 1

Grunberg Gregory · CIK 0001711080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Read SEC document
April 15, 2021 Filed Apr 19, 2021 16:51 UTC 89bio, Inc. ETNB · Entity 73682 GrantStock Option (Right to Buy) · Derivative 12,500 $0.00 Strike: $24.16 $0.00
Disclosure

SEC source: 0000899243-21-016233 · doc4.xml · derivative · entry 1

Grunberg Gregory · CIK 0001711080 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2031-04-15

F1 · derivative.exercise_date: This option represents a right to purchase a total of 12,500 shares of the Issuer's Common Stock, one third of which will vest on April 15, 2022, with the remaining two thirds vesting in equal monthly installments over the following two years, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:09 UTC 89bio, Inc. ETNB · Entity 73682 OtherCommon Stock 850 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-031486 · doc4.xml · nonDerivative · entry 2

Grunberg Gregory · CIK 0001711080 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 850

F3 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members.

Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:09 UTC 89bio, Inc. ETNB · Entity 73682 OtherCommon Stock 850,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-031486 · doc4.xml · nonDerivative · entry 1

Grunberg Gregory · CIK 0001711080 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,750,877

F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("Longitude Venture III") to its general and limited partners.

F2 · ownership.nature: These shares are held directly by Longitude Venture III. Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III. The Reporting Person is a member of Longitude Capital III and may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interests therein.

Read SEC document
July 10, 2020 Filed Jul 14, 2020 20:08 UTC 89bio, Inc. ETNB · Entity 73682 PurchaseCommon Stock 109,090 $27.50 $2,999,975.00
Disclosure

SEC source: 0000899243-20-019122 · doc4.xml · nonDerivative · entry 1

Grunberg Gregory · CIK 0001711080 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,600,877

F1 · shares: On July 10, 2020, Longitude Venture Partners III, L.P. ("Longitude Venture III") purchased 109,090 shares of the Issuer's common stock at a price of $27.50 per share in the Issuer's follow-on public offering.

F2 · ownership.nature: These shares are held directly by Longitude Venture III. Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III. The Reporting Person is a member of Longitude Capital III and may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interests therein.

Read SEC document
June 25, 2020 Filed Jun 29, 2020 21:48 UTC KALA BIO, Inc. KALA · Entity 7964 GrantCommon Stock 20,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-20-078310 · a4.xml · nonDerivative · entry 1

Grunberg Gregory · CIK 0001711080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service with the Issuer, the RSUs will vest as to 100% of the shares underlying the RSUs on the earlier of (i) June 25, 2021 or (ii) the date of the first annual meeting following June 25, 2020.

F2 · balance_after: Includes 20,000 unvested RSUs.

Read SEC document
June 22, 2020 Filed Jul 14, 2020 17:03 UTC 89bio, Inc. ETNB · Entity 73682 GrantStock Option (Right to Buy) · Derivative 7,000 $0.00 Strike: $24.29 $0.00
Disclosure

SEC source: 0000899243-20-019091 · doc4.xml · derivative · entry 1

Grunberg Gregory · CIK 0001711080 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Stock · 7,000 shares

Expires 2030-06-22

F1 · derivative.exercise_date: This option represents a right to purchase a total of 7,000 shares of the Issuer's Common Stock, which will vest in full on June 22, 2021, subject to the Reporting Person's continued service to the Issuer through such date.

Read SEC document
April 05, 2020 Filed Apr 7, 2020 16:15 UTC 89bio, Inc. ETNB · Entity 73682 GrantStock Option (Right to Buy) · Derivative 7,000 $0.00 Strike: $21.40 $0.00
Disclosure

SEC source: 0000899243-20-010402 · doc4.xml · derivative · entry 1

Grunberg Gregory · CIK 0001711080 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Stock · 7,000 shares

Expires 2030-04-05

F1 · derivative.exercise_date: This option represents a right to purchase a total of 7,000 shares of the Issuer's Common Stock, one third of which will vest on April 5, 2021, with the remaining two thirds vesting in equal monthly installments over the following two years, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Read SEC document
March 13, 2020 Filed Mar 16, 2020 07:59 UTC KALA BIO, Inc. KALA · Entity 7964 PurchaseCommon Stock 2,534,854 $7.89 $19,999,998.06
Disclosure

SEC source: 0001179110-20-003675 · edgar.xml · nonDerivative · entry 1

Grunberg Gregory · CIK 0001711080 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Longitude Venture Partners IV, L.P.

Disclosed balance after: 2,534,854

F1 · ownership.nature: Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of Longitude Venture Partners IV, L.P. ("LVP IV") and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright, Juliet Tammenoms Bakker are the managing members of LCP IV. Each of LCP IV, Mr. Enright, Ms. Tammenoms Bakker and the Reporting Person (a member of the Issuer's board of directors) disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Read SEC document
November 13, 2019 Filed Nov 13, 2019 19:04 UTC 89bio, Inc. ETNB · Entity 73682 ConversionSeries A Preferred Stock · Derivative 11,916,667 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-027222 · doc4.xml · derivative · entry 3

Grunberg Gregory · CIK 0001711080 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,916,787 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date.

F2 · derivative.exercise_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date.

F2 · derivative.expiration_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date.

F3 · ownership.nature: These shares are held directly by Longitude Venture III. Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III. The Reporting Person is a member of Longitude Capital III and may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interests therein.

Read SEC document
November 13, 2019 Filed Nov 13, 2019 19:04 UTC 89bio, Inc. ETNB · Entity 73682 ConversionCommon Stock 1,916,787 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-027222 · doc4.xml · nonDerivative · entry 2

Grunberg Gregory · CIK 0001711080 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,491,787

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date.

F3 · ownership.nature: These shares are held directly by Longitude Venture III. Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III. The Reporting Person is a member of Longitude Capital III and may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interests therein.

Read SEC document
November 11, 2019 Filed Nov 13, 2019 19:04 UTC 89bio, Inc. ETNB · Entity 73682 PurchaseCommon Stock 575,000 $16.00 $9,200,000.00
Disclosure

SEC source: 0000899243-19-027222 · doc4.xml · nonDerivative · entry 1

Grunberg Gregory · CIK 0001711080 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 575,000

F1 · shares: On November 11, 2019, Longitude Venture Partners III, L.P. ("Longitude Venture III") purchased 575,000 shares of the Issuer's common stock at a price of $16.00 per share in the Issuer's initial public offering.

F3 · ownership.nature: These shares are held directly by Longitude Venture III. Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III. The Reporting Person is a member of Longitude Capital III and may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interests therein.

Read SEC document
June 05, 2019 Filed Jun 7, 2019 16:02 UTC KALA BIO, Inc. KALA · Entity 7964 GrantStock Option (right to buy) · Derivative 21,000 $0.00 Strike: $5.35 $0.00
Disclosure

SEC source: 0001104659-19-034522 · a4.xml · derivative · entry 1

Grunberg Gregory · CIK 0001711080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,000

Underlying: Common Stock · 21,000 shares

Expires 2029-06-04

F1 · derivative.exercise_date: This option was granted on June 5, 2019 and vests with respect to 1/12th of the shares underlying the option at the end of each successive one-month period thereafter.

Read SEC document
October 05, 2018 Filed Oct 9, 2018 16:46 UTC KALA BIO, Inc. KALA · Entity 7964 PurchaseCommon Stock 606,060 $8.25 $4,999,995.00
Disclosure

SEC source: 0001179110-18-012105 · edgar.xml · nonDerivative · entry 1

Grunberg Gregory · CIK 0001711080 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Longitude Venture Partners II, L.P.

Disclosed balance after: 2,877,006

F1 · ownership.nature: These shares are held by Longitude Venture Partners II, L.P. The Reporting Person is a member of Longitude Capital Partners II, LLC, the general partner of Longitude Venture Partners II, L.P., and may be deemed to share voting and investment power over these shares. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Read SEC document
June 12, 2018 Filed Jun 14, 2018 16:47 UTC KALA BIO, Inc. KALA · Entity 7964 GrantStock Option (right to buy) · Derivative 12,960 $0.00 Strike: $13.73 $0.00
Disclosure

SEC source: 0001179110-18-008526 · edgar.xml · derivative · entry 1

Grunberg Gregory · CIK 0001711080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,960

Underlying: Common Stock · 12,960 shares

Expires 2028-06-11

F1 · derivative.exercise_date: This option was granted on June 12, 2018 and vests in equal monthly installments until the one-year anniversary of the date of grant and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

Read SEC document
July 25, 2017 Filed Jul 26, 2017 16:31 UTC KALA BIO, Inc. KALA · Entity 7964 ConversionSeries C Preferred Stock · Derivative 10,707,985 $0.00 $0.00
Disclosure

SEC source: 0001179110-17-010704 · edgar.xml · derivative · entry 3

Grunberg Gregory · CIK 0001711080 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Longitude Venture Partners II, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 2,055,946 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · derivative.exercise_date: The Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F1 · derivative.expiration_date: The Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F4 · ownership.nature: These shares were held by Longitude Venture Partners II, L.P. The Reporting Person is a member of Longitude Capital Partners II, LLC, the general partner of Longitude Venture Partners II, L.P., and may be deemed to share voting and investment power over these shares. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Read SEC document
July 25, 2017 Filed Jul 26, 2017 16:31 UTC KALA BIO, Inc. KALA · Entity 7964 PurchaseCommon Stock 215,000 $15.00 $3,225,000.00
Disclosure

SEC source: 0001179110-17-010704 · edgar.xml · nonDerivative · entry 2

Grunberg Gregory · CIK 0001711080 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Longitude Venture Partners II, L.P.

Disclosed balance after: 2,270,946

F2 · ownership.nature: These shares are held by Longitude Venture Partners II, L.P. The Reporting Person is a member of Longitude Capital Partners II, LLC, the general partner of Longitude Venture Partners II, L.P., and may be deemed to share voting and investment power over these shares. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F3 · ownership.nature: Includes 215,000 shares of Common Stock acquired by Longitude Venture Partners, II, L.P in the Issuer's initial public offering.

Read SEC document
July 25, 2017 Filed Jul 26, 2017 16:31 UTC KALA BIO, Inc. KALA · Entity 7964 ConversionCommon Stock 2,055,946 Not disclosed Not disclosed
Disclosure

SEC source: 0001179110-17-010704 · edgar.xml · nonDerivative · entry 1

Grunberg Gregory · CIK 0001711080 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Longitude Venture Partners II, L.P.

Disclosed balance after: 2,055,946

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2 · ownership.nature: These shares are held by Longitude Venture Partners II, L.P. The Reporting Person is a member of Longitude Capital Partners II, LLC, the general partner of Longitude Venture Partners II, L.P., and may be deemed to share voting and investment power over these shares. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Read SEC document
July 19, 2017 Filed Jul 21, 2017 16:20 UTC KALA BIO, Inc. KALA · Entity 7964 GrantStock Option (right to buy) · Derivative 12,960 $0.00 Strike: $15.00 $0.00
Disclosure

SEC source: 0001179110-17-010593 · edgar.xml · derivative · entry 1

Grunberg Gregory · CIK 0001711080 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,960

Underlying: Common Stock · 12,960 shares

Expires 2027-07-18

F1 · derivative.exercise_date: This option was granted, effective on July 19, 2017 and vests over one year, with 8.33% of the shares underlying the option vesting on August 19, 2017, and an addition 8.33% of the shares underlying the option vesting at the end of each successive one-month period thereafter.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.